Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, expanding its oncology pipeline into dual-payload antibody-drug conjugates. CrossBridge’s platform is designed to deliver two distinct cytotoxic payloads from a single antibody, aiming for complementary cell-killing effects on tumor targets. CrossBridge’s lead asset, CBB-120, is expected to move toward an investigational new drug application with the FDA later in 2026. Lilly’s deal reflects continued pharma emphasis on ADC differentiation and payload strategy as the modality matures across earlier lines of therapy.